Vicagrel - Jiangsu Vcare Pharmatech/China Pharmaceutical University

Drug Profile

Vicagrel - Jiangsu Vcare Pharmatech/China Pharmaceutical University

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator China Pharmaceutical University; Jiangsu Vcare Pharmatech
  • Developer Jiangsu Vcare Pharmatech
  • Class 2 ring heterocyclic compounds; Antiplatelets; Antithrombotics; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute coronary syndromes

Most Recent Events

  • 13 Jul 2018 Jiangsu vcare pharmaceutical technology plans a phase II trial for Acute coronary syndrome in China , (ChiCTR1800017069)
  • 28 May 2018 No recent reports of development identified for preclinical development in Acute coronary syndromes in China (PO)
  • 03 Oct 2016 Jiangsu Vcare Pharmatech plans a phase I trial for Acute coronary syndromes in China (ChiCTR-IIR-16009260)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top